Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.